[Pharmacokinetics and tolerance of an orally administered combination preparation containing phenylbutazone and prednisolone in the dog].
Tolerance and pharmacokinetics of a combination of phenylbutazone and prednisolone (tablets) were studied in Beagle dogs. For two weeks, the drug was administered orally (3.33 mg/kg phenylbutazone combined with 0.1 mg/kg prednisolone and 6.66 mg/kg phenylbutazone combined with 0.3 mg/kg prednisolone twice daily). The dosage was reduced to 50 per cent after one week. No signs of intolerance were found. After treatment with 3.33 mg/kg phenylbutazone, a plasma concentration of 10 micrograms/ml was reached within 1 to 2 hours. No prednisolone concentration above 2 ng/kg was measured. Additionally, a synergistic antiinflammatory effect of the two ingredients was obvious (hind paw dextran edema in rats). In addition to results of ENGELKE et al. (1995) who studied the clinical efficacy of the combination, the presented data demonstrate a good tolerance.
Kietzmann
M
M
Klinik für kleine Haustiere, Tierärztlichen Hochschule Hannover.
Meyer-Lindenberg
A
A
Engelke
A
A
Nolte
I
I
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D004285:Dogs / Q000378:metabolism*; D004338:Drug Combinations; D005260:Female; D008297:Male; D010653:Phenylbutazone / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D011239:Prednisolone / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D013607:Tablets
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D013607:Tablets; D011239:Prednisolone; D010653:Phenylbutazone
Pharmakokinetik und Verträglichkeit eines oral verabreichten Kombinationspräparates mit den Inhaltsstoffen Phenylbutazon und Prednisolon beim Hund.